Current guidelines from the College of American Pathologists, International Association for the Study of Lung Cancer (IASLC), and the Association of Molecular Pathology recommend testing for EGFR (Epidermal Growth Factor Receptor) mutations, ALK rearrangements, ROS1 rearrangements, BRAF, RET rearrangements, and MET exon 14 skipping mutations for newly diagnosed lung adenocarcinoma [20]. This evidence concerns the gene EGFR and lung adenocarcinoma.